On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at ...

Accurate measurement of HMGB-1, neopterin and sIL-2R supports reliable assessment of immune activation across clinical and ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and ...

Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Adam Broerman, a graduate student in the University of Washington’s Institute for Protein Design, studies an engineered protein that can turn off protein interactions. (IPD Photo / Ian Haydon) The ...

BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...

A phase I study showed activity with WTX-124, a novel interleukin-2 (IL-2) prodrug, in patients with locally advanced or metastatic solid cancers whose tumors progressed after checkpoint inhibition.

BIRMINGHAM, Ala. – The immune system has a biological telecommunications system — small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense ...